China (Mainland)
Premiumsupplier
Human Bnp-32 Nesiritide Brain Natriuretic Peptide for Heart Failure CAS NO.124584-08-3
- Min.Order: 1 Gram
- Payment Terms: L/C,T/T
- Product Details
Keywords
- Nesiritide, Несиритид,nesiritida,nésiritide
- Acetato de nesiritida,Несиритид ацетат,nesiritida
- Acétate de nésiritide, Acetato de nesiritida
Quick Details
- ProName: Human Bnp-32 Nesiritide Brain Natriure...
- CasNo: 124584-08-3
- Molecular Formula: C143h244n50o42s4
- Appearance: white to off white
- Application: Nesiritide should be considered for p...
- DeliveryTime: Ready in Stock
- PackAge: Aluminum Foil Bag
- Port: HK/Shenzhen
- ProductionCapacity: 500 Kilogram/Year
- Purity: ≥98%
- Storage: 2-8 degree
- Transportation: Cold chain and cool storage delivery f...
- LimitNum: 1 Gram
Superiority
The first listed company in peptides industry, mature process, stable and advaced technology,API capacity reachease to 500kg with 3 main factory sites.
Details
Nesiritide (BNP-32), know as B-Type Natriuretic Peptide, BNP 32, Brain Natriuretic Peptide 32, Type-B Natriuretic Peptide, Ventricular Natriuretic Peptide, B type.
Product Description
Human BNP serves to compensate for deteriorating cardiac function causing preload and afterload reductions, natriuresis, diuresis, suppression of the renin-angiotensin-aldosterone system (RAAS) and endothelin-1, and lowering of norepinephrine. Based on its unique pharmacologic profile, nesiritide results in clinically significant balanced vasodilation of arteries and veins, and may be well suited for patients presenting with various scenarios of decompensated CHF usually due to volume overload (NYHA classes II-IV).
Unlike nitroglycerin, tachyphylaxis did not appear to occur with Natrecor. The complete efficacy profile of nesiritide included preload reduction (PCWP and RAP), reductions in pulmonary artery pressures, afterload reduction (systemic vascular resistance), and increases in cardiac index and stroke volume index (which are dose-dependent and not the result of a direct inotropic effect), without increasing heart rate.
Unlike inotropes, the beneficial hemodynamic effects produced by nesiritide do not cause an increase in myocardial oxygen consumption (MVO2), an important consideration for patients with acutely decompensated heart failure. Because Nesiritide is not an inotrope, it does not affect myocardial contractility, as does a beta-adrenergic receptor agonist, or a phosphodiesterase III inhibitor. As a result, nesiritide is not arrhythmogenic.
